Baxter International Inc. earnings overview

BAX FY2026 Q1 · Calendar Q2 2026

Baxter International Inc.

Baxter delivered a Q1 beat with adjusted EPS of $0.36 versus the $0.311 consensus and revenue of $2.70B (+3 percent reported, -1 percent organic) above the $2.62B estimate. The market responded positively with a 4.0 percent session move and 6.8 percent subsequent drift, suggesting investors are rewarding early turnaround progress, particularly the swing to positive free cash flow of $76M from negative $221M a year ago. However, the Novum infusion-pump shipment hold, tariff pressures, and supply constraints at a contract manufacturer remain material headwinds. Management maintained full-year guidance of flat to 1 percent reported sales growth with 13 to 14 percent operating margin, and the cautious tone reflects unresolved execution risk around pump remediation and the cost environment. The stock trades at $26.20, above the analyst consensus target of $23.43, indicating the market is…